ArticleClinical and translational medicine2022
Clinical and transcriptomic features of persistent exacerbation-prone severe asthma in U-BIOPRED cohort.
Article in Clinical and translational medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 21 citations in OpenAlex.
- Aberrant mucin expression and keratinization distinguishing severe from mild asthma revealed by interpretable machine learning.JCI insight · 2026Article
- Proteomic and Transcriptomic Signatures of Poor Asthma Symptom Control in the U-BIOPRED Cohort.Allergy · 2026Article
- Article
- Multi-omics identifies severe asthma endotypes linked toThe World Allergy Organization journal · 2025Article
- Single-cell transcriptomic profiling of eosinophils and airway immune cells in childhood asthma.The Journal of allergy and clinical immunology · 2025Article
- Frequent exacerbator-a novel endotype of pediatric asthma.The Journal of allergy and clinical immunology · 2025Review
- Exploring the Role of Lactoferrin in Managing Allergic Airway Diseases among Children: Unrevealing a Potential Breakthrough.Nutrients · 2024Review
- Multi-omics in nasal epithelium reveals three axes of dysregulation for asthma risk in the African Diaspora populations.Nature communications · 2024Article
- Role of Complement Components in Asthma: A Systematic Review.Journal of clinical medicine · 2024Review
- Roles of glutamic pyruvate transaminase 2 in reprogramming of airway epithelial lipidomic and metabolomic profiles after smoking.Clinical and translational medicine · 2024Article
- Integrated study of systemic and local airway transcriptomes in asthma reveals causal mediation of systemic effects by airway key drivers.Genome medicine · 2023Article
- Airway transcriptome networks identify susceptibility to frequent asthma exacerbations in children.The Journal of allergy and clinical immunology · 2023Article
- Asthma Exacerbations: The Genes Behind the Scenes.Journal of investigational allergology & clinical immunology · 2023Review
- Systems Biology in Asthma.Advances in experimental medicine and biology · 2023Article
- Innate Immunity, Epithelial Plasticity, and Remodeling in Asthma.Advances in experimental medicine and biology · 2023Article
- Determining asthma endotypes and outcomes: Complementing existing clinical practice with modern machine learning.Cell reports. Medicine · 2022Review
- Complex pathways leading to future paediatric asthma exacerbations.ERJ open research · 2022Article
- Eosinophilic inflammation: An Appealing Target for Pharmacologic Treatments in Severe Asthma.Biomedicines · 2022Review
- From spirometry to spatial omics in pursuit of asthma endotypes.Clinical and translational medicine · 2022Article
- Frequent exacerbators in severe asthma: Focus on clinical and transcriptional factors.Clinical and translational medicine · 2022Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
37 authors at 19 institutions in 10 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundExacerbation-prone asthma is a feature of severe disease. However, the basis for its persistency remains unclear.
objectivesTo determine the clinical and transcriptomic features of frequent exacerbators (FEs) and persistent FEs (PFEs) in the U-BIOPRED cohort.
methodsWe compared features of FE (≥2 exacerbations in past year) to infrequent exacerbators (IE, <2 exacerbations) and of PFE with repeat ≥2 exacerbations during the following year to persistent IE (PIE). Transcriptomic data in blood, bronchial and nasal epithelial brushings, bronchial biopsies and sputum cells were analysed by gene set variation analysis for 103 gene signatures.
resultsOf 317 patients, 62.4% had FE, of whom 63.6% had PFE, while 37.6% had IE, of whom 61.3% had PIE. Using multivariate analysis, FE was associated with short-acting beta-agonist use, sinusitis and daily oral corticosteroid use, while PFE was associated with eczema, short-acting beta-agonist use and asthma control index. CEA cell adhesion molecule 5 (CEACAM5) was the only differentially expressed transcript in bronchial biopsies between PE and IE. There were no differentially expressed genes in the other four compartments. There were higher expression scores for type 2, T-helper type-17 and type 1 pathway signatures together with those associated with viral infections in bronchial biopsies from FE compared to IE, while there were higher expression scores of type 2, type 1 and steroid insensitivity pathway signatures in bronchial biopsies of PFE compared to PIE.
conclusionThe FE group and its PFE subgroup are associated with poor asthma control while expressing higher type 1 and type 2 activation pathways compared to IE and PIE, respectively.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.